Pharmaceutical

Sanders issues warning to Novo Nordisk amid GLP-1 drug ...

The US Senator took another swipe at the US prices of Novo Nordisk’s blockbuster...

Erasca trims workforce and pipeline to focus on KRAS an...

Erasca has made operational cuts while licensing a molecular glue therapy and a ...

Galapagos enters deal to boost decentralised CAR-T ther...

Galapagos has signed a partnership with Blood Centers of America to expedite dec...

FDA grants breakthrough therapy status for Nuvalent’s N...

The US FDA has granted breakthrough therapy designation (BTD) for Nuvalent’s NVL...

CinDome Pharma secures $40m to advance gastroparesis tr...

CinDome Pharma has secured $40m in a Series B financing extension round to devel...

LUNA-18 by Chugai Pharmaceutical for Solid Tumor: Likel...

LUNA-18 is under clinical development by Chugai Pharmaceutical and currently in ...

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster...

LZ-901 is under clinical development by Beijing Luzhu Biotechnology and currentl...

MRNA-1365 by Moderna for Human Metapneumovirus Infectio...

MRNA-1365 is under clinical development by Moderna and currently in Phase I for ...

LY-3541860 by Eli Lilly and Co for Relapsing Multiple S...

LY-3541860 is under clinical development by Eli Lilly and Co and currently in Ph...

TT-01488 by TransThera Sciences (Nanjing) for Mantle Ce...

TT-01488 is under clinical development by TransThera Sciences (Nanjing) and curr...

Influenza (quadrivalent) vaccine by Pfizer for Influenz...

Influenza (quadrivalent) vaccine is under clinical development by Pfizer and cur...

Opzelura by Incyte for Graft Versus Host Disease (GVHD)...

Opzelura is under clinical development by Incyte and currently in Phase II for G...

Influenza (quadrivalent) vaccine by Pfizer for Influenz...

Influenza (quadrivalent) vaccine is under clinical development by Pfizer and cur...

Opzelura by Incyte for Chronic Cutaneous Lupus Erythema...

Opzelura is under clinical development by Incyte and currently in Phase II for C...

SCDARIC-33 by Regeneron Pharmaceuticals for Refractory ...

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and curren...

Bayer reports drop in Q1 sales amidst patent litigation...

Bayer announced a fall in Q1 sales and predicted future challenges in the Xarelt...